Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 20;12(9):1048.
doi: 10.3390/v12091048.

The Emergence of a vv + MDV Can Break through the Protections Provided by the Current Vaccines

Affiliations

The Emergence of a vv + MDV Can Break through the Protections Provided by the Current Vaccines

Meng-Ya Shi et al. Viruses. .

Abstract

Marek's disease (MD) is an infectious malignant T-cell lymphoma proliferative disease caused by Marek's disease virus (MDV). In recent years, the emergence of very virulent (vv) and/or very virulent plus (vv +) strains of MDV in the field has been suggested as one of the causes of vaccination failure. The pathogenicity of the MDV strain GX18NNM4, isolated from a clinical outbreak in a broiler breeder flock that was vaccinated with CVI988/Rispens, was investigated. In the vaccination-challenge test, GX18NNM4 was able to break through the protections provided by the vaccines CVI988 and 814. It also significantly reduced body weight gain and caused marked gross lesions and a large area of infiltration of neoplastic lymphocyte cells in the heart, liver, pancreas, etc. of the infected birds. In addition, the expressions of programmed death 1 (PD-1) and its ligand, programmed death ligand 1 (PD-L1), in the spleens and cecal tonsils (CTs) of the unvaccinated challenged birds were significantly increased compared to those in the vaccinated challenged birds, indicating that the PD-1/PD-L1 pathway is related to immune evasion mechanisms. The results showed that the GX18NNM4 strain could cause severe immunosuppression and significantly decrease the protections provided by the current commercial vaccines, thus showing GX18NNM4 to be a vv + MDV strain.

Keywords: Marek’s disease virus; immunosuppression; pathogenicity analysis; protection index; vv + MDV.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Statistics of body weight of experimental birds (X ± SD). Means not sharing a common letter are significantly different (p < 0.05).
Figure 2
Figure 2
Dynamics of immune organ indices of the experimental birds. (A) spleen; (B) thymus; (C) bursa. Means not sharing a common letter are significantly different (p < 0.05).
Figure 3
Figure 3
The viral load of MDV in the peripheral blood lymphocytes (PBLs) of the experimental birds. Means not sharing a common letter are significantly different (p < 0.05).
Figure 4
Figure 4
The mRNA expressions of PD-1 and PD-L1 in the tissues from birds experimentally infected with MDV. (A) PD-1 in the spleen; (B) PD-1 in the cecal tonsils; (C) PD-L1 in the spleen; (D) PD-L1 in the cecal tonsils. Determined by real-time PCR. Means not sharing a common letter are significantly different (p < 0.05).
Figure 5
Figure 5
Survival patterns showing the overall effects of the various treatments.
Figure 6
Figure 6
Anatomical and histological lesions: (A,L) white solid nodules in the lungs; (E,P) numerous proliferating tumor cells concentrated in the lung tissue; (B,D,J) tumor or tumor-like lesions in the heart; (F,H,N) numerous infiltrations of diffuse lymphocytosis in myocardial fibers; (C) pancreas hemorrhage with tumor; (G) numerous lymphocytosis proliferations in pancreas; (I) white tumor nodules, approximately 1–3 mm in diameter, on the liver surface; (M) numerous proliferating tumor cells were concentrated in the hepatic tissue; (K) white tumor nodule on the surface of spleen; (O) large number of lymphocytes infiltrated in the spleen tissue.

References

    1. Nolan L.K., Swayne D.E., Saif Y.M., Fadly A.M., Glisson J.R., Mcdougald L.R. Diseases of Poultry. Wiley; Hoboken, NJ, USA: 2016. pp. 513–673.
    1. Biggs P.M. The History and Biology of Marek’s Disease Virus. Curr. Top. Microbiol. Immunol. 2001;255:1–24. doi: 10.1007/978-3-642-56863-3_1. - DOI - PubMed
    1. Osterrieder N., Kamil J.P., Schumacher D., Tischer B.K., Trapp S. Marek’s disease virus: From miasma to model. Nat. Rev. Microbiol. 2006;4:283–294. doi: 10.1038/nrmicro1382. - DOI - PubMed
    1. Bertzbach L.D., Conradie A.M., You Y., Kaufer B.B. Latest Insights into Marek’s Disease Virus Pathogenesis and Tumorigenesis. Cancers. 2020;12:647. doi: 10.3390/cancers12030647. - DOI - PMC - PubMed
    1. Morrow C., Fehler F. 5-Marek’s disease: A worldwide problem. In: Davison F., Nair V., editors. Marek’s Disease. Academic Press; Oxford, UK: 2004. pp. 49–61.

Publication types